CATALOGO DEI PRODOTTI DELLA RICERCA

FATTOVICH, Giovanna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.942
EU - Europa 12.832
AS - Asia 8.703
SA - Sud America 1.109
AF - Africa 100
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 10
Totale 36.708
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.820
RU - Federazione Russa 4.269
SG - Singapore 4.035
GB - Regno Unito 3.699
CN - Cina 2.907
FR - Francia 1.087
BR - Brasile 931
DE - Germania 856
IE - Irlanda 781
SE - Svezia 702
HK - Hong Kong 633
FI - Finlandia 526
IT - Italia 514
KR - Corea 374
VN - Vietnam 322
UA - Ucraina 172
TR - Turchia 95
CA - Canada 69
AR - Argentina 66
IN - India 59
BD - Bangladesh 47
JP - Giappone 40
PL - Polonia 40
ID - Indonesia 31
AT - Austria 29
ES - Italia 29
MX - Messico 27
ZA - Sudafrica 26
EC - Ecuador 25
BE - Belgio 23
IQ - Iraq 21
NL - Olanda 21
VE - Venezuela 20
TN - Tunisia 19
PE - Perù 17
UZ - Uzbekistan 17
CO - Colombia 16
AE - Emirati Arabi Uniti 14
CL - Cile 14
LT - Lituania 12
MA - Marocco 12
PK - Pakistan 12
AZ - Azerbaigian 11
PY - Paraguay 10
EG - Egitto 9
EU - Europa 9
KE - Kenya 9
PS - Palestinian Territory 9
UY - Uruguay 9
DZ - Algeria 8
IL - Israele 8
SA - Arabia Saudita 8
AU - Australia 7
JO - Giordania 7
BG - Bulgaria 6
CZ - Repubblica Ceca 6
GA - Gabon 6
KG - Kirghizistan 6
PT - Portogallo 6
RO - Romania 6
SN - Senegal 6
AL - Albania 5
CH - Svizzera 5
GR - Grecia 5
HU - Ungheria 5
MD - Moldavia 5
NP - Nepal 5
PA - Panama 5
DO - Repubblica Dominicana 4
GE - Georgia 4
HN - Honduras 4
IR - Iran 4
LV - Lettonia 4
NO - Norvegia 4
RS - Serbia 4
TH - Thailandia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BH - Bahrain 3
KZ - Kazakistan 3
LB - Libano 3
NZ - Nuova Zelanda 3
PH - Filippine 3
SK - Slovacchia (Repubblica Slovacca) 3
BB - Barbados 2
BN - Brunei Darussalam 2
CR - Costa Rica 2
EE - Estonia 2
ET - Etiopia 2
HR - Croazia 2
JM - Giamaica 2
KH - Cambogia 2
KW - Kuwait 2
MY - Malesia 2
NI - Nicaragua 2
OM - Oman 2
QA - Qatar 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AO - Angola 1
BJ - Benin 1
Totale 36.695
Salva come PNG Salva come JPEG
Città #
Southend 2.941
Jacksonville 2.515
Singapore 1.879
Woodbridge 1.526
Chandler 1.414
Moscow 1.250
Ashburn 940
Ann Arbor 934
Dallas 930
Houston 831
Dublin 781
Hong Kong 628
Wilmington 418
Lawrence 372
Princeton 371
Lancaster 356
Nanjing 303
Jinan 274
Beijing 263
The Dalles 263
Sindelfingen 262
Shenyang 221
Los Angeles 214
New York 201
Buffalo 180
Kent 149
Hebei 145
Ho Chi Minh City 128
Tianjin 123
Changsha 121
Zhengzhou 105
Boardman 97
Haikou 91
Nanchang 90
Milan 87
Helsinki 78
São Paulo 75
Taizhou 75
Redondo Beach 74
Verona 74
Jiaxing 73
Columbus 71
Guangzhou 70
Hangzhou 69
Hanoi 69
Ningbo 69
Taiyuan 61
Norwalk 50
Santa Clara 47
Washington 47
Seattle 45
Munich 43
Falls Church 42
Lanzhou 41
Tokyo 36
Nuremberg 34
Chicago 31
Brooklyn 28
Council Bluffs 28
Philadelphia 28
San Francisco 28
Rio de Janeiro 27
Stockholm 26
Warsaw 24
Seoul 23
Fuzhou 22
Belo Horizonte 21
Toronto 21
Brussels 20
Boston 19
Turku 19
Auburn Hills 18
Falkenstein 17
Montreal 17
Tashkent 17
Phoenix 16
Atlanta 15
Rome 15
Lima 14
Porto Alegre 14
Shanghai 14
Brasília 13
Dearborn 13
Dhaka 13
Fairfield 13
Johannesburg 13
Chennai 12
Elk Grove Village 12
Goiânia 12
Jakarta 12
Vienna 12
Amsterdam 11
Baku 11
Buenos Aires 11
Da Nang 11
Frankfurt am Main 11
Haiphong 11
London 11
Mehlingen 11
Qingdao 11
Totale 23.392
Salva come PNG Salva come JPEG
Nome #
Metodo radioimmunologico ed elettrosineresi nello studio dell'antigene Australia (HBAg) e dell'anticorpo (HBAc). Risultati comparativi 297
Accuracy of ultrasound in the detection of liver fibrosis in chronic viral hepatitis. 285
A 25 years longitudina study of hepatitis B e antigen positive chornic hepatitis B in italian patients 198
Endogenously produced TNF-α contributes to the expression of CXCL10/IP-10 in IFN-λ3-activated plasmacytoid dendritic cells 181
A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone. 180
A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B. 175
Protease inhibitors-based therapy induces acquired spherocytic-like anemia and ineffective erythropoiesis in chronic HCV patients 171
A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. 170
Progression to cirrhosis and mortality of chronic hepatiita type B: a cohort study with 25 years follow-up in Italy. 170
La regressione della cirrosi epatica: non più un mito. 169
Interaction between vitamin D binding protein polymorphisms and vitamin D levels in the prediction of antiviral response in chronic hepatitis C. 166
Accuracy of VirtualTouch Acoustic Radiation Force Impulse (ARFI) Imaging for the Diagnosis of Cirrhosis during Liver Ultrasonography 165
The homestasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. 162
Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome. 159
A controlled trial of lymphoblastoid interferon for chronic anti-HBe/HBV-DNA positive hepatitis 158
[Infection due to hepatitis B virus and host immune response] 154
Interleukin-28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C under real-life conditions 153
A long term study of hepatitis G virus coinfection in chronic hepatitis B 152
Genetic polymorphysms of vitamin d pathway predict antiviral treatment outcome in slow responder naive patients with chronic hepatitis C 152
Hepcidin suppression relative to iron status in patients with chronic Hepatitits C 150
A multicenter prospective observational study to evaluate factors influencing efficacy, tolerance and compliance to antiviral treatment with interferon and ribavirin in daily clinical practice 150
Natural history of hepatitis B e antigen positive chronic hepatitis B in italian patients: a 25 years longitudinal study 150
A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. 149
TLR4 rs4986790 A>G genetic polymorphisms predict liver fibrosis severity in Caucasian patients with chronic hepatitis C. 149
Autoantibodies during alpha-interferon therapy for chronic hepatitis B 148
Effect of hepatitis B and C virus infection on the natural history of compensated cirrhosis: a cohort study of 297 patients. 148
Long-term outcome of chronic hepatitis B in caucasian patients: mortality after 25 years 148
HCV gentotype 3 and circulating squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV infected patients. 148
Hepatitis C virus genotype and prognosis of compensated cirrhosis type C 147
A randomized study comparing 48 and 96 weeks peginterferon alfa-2a therapy in genotype D HBeAg negative chronic hepatitis B. 145
Interaction between vitamin D binding protein polymorphisms and vitamin D levels in the prediction of antiviral response in chronic hepatitis C. 145
Consensus interferon (CIFN) in combination with ribavirin (RBV) for naive patients with chronic hepatitis C: a multicenter study 143
Autonomic dysfunction and hemodynamic derangement in cirrhotic cardiomyopathy 143
Malattie autoimmuni del fegato 141
[Relationships between clinico-therapeutic parameters and immunological status in patients with lung cancer] 140
A survey of clinical toxicity of alfa interferon in 11.241 patients with chronic viral hepatitis 140
Hepatocellularcarcinoma in cirrhosis: incidence and risk factors. 140
A controlled trial of alpha-2 recombinant interferon for chronic HBeAg positive hepatitis 139
Insulin resistance is not a relevant predictor of sustained virologic response in chronic hepatitis C patients: results from the Italian hepatitis C cohort study (ITAHECS) collaborative group 136
Influence of hepatitis delta virus infection on clinical outcome of compensated cirrhosis type B 135
Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C 135
A multicenter randomized double-blind placebo-controlled trial of interleukin-2 in chronic hepatitis B 134
A controlled trial of thymopentin therapy in HBV-DNA positive chronic hepatitis B 134
[Presence of HBsAg and IgG on the membrane of hepatic cells in patients with acute and chronic hepatitis] 133
Natural course and prognostic factors of hepatitis B. 132
Final report of a consensus interferon (CIFN) plus ribavirin (RBV) study for chronic hepatitis C (CHC) 132
Carriage of the EGF RS4444903 A>G functional polimorphism associates with disease progression in chronic HBV infection. 132
Membrane oxidative damage causes hemolitic anemia during ribavirin therapy for chronic hepatitis C 131
Natural history of hepatitis B and prognostic factors of disease progression 131
Host genetics regulates liver fibrosis progression in patients with chronic hepatitis C (CHC) 131
Efficacy of prolonged high dose of interferon (IFN) plus ribavirin in young genotype 1/4 patients with chronic hepatitis C not responding to IFN alone 131
PEG-interferon and ribavirin in HCV-related cirrhotic patients with profound thrombocytopenia. 131
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C 131
Natural history of hepatitis B virus infection and disease 130
A seven-gene signature (Cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C 130
Natural history of chronic hepatitis B 130
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C 130
Role of membrane oxidative damage in the pathogenesis of hemolitic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection 128
Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C. 128
Efficacy and safety of consensus interferon (CIFN) plus ribavirin (RBV) for naive patients with chronic hepatitis C (CHC): final report of a pilot study 128
Interferon (IFN) induction followed by prolonged high dose IFN in combination with ribavirin (RBV) for relapsers HCV patients: a randomized controlled multicenter trial 128
Suppressor cell function in chronic active hepatitis 128
Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily clinical parameters. 126
-smooth-muscle actin expression in chronic viral hepatitis before and after interferon therapy 125
Incidenza e fattori di rischio di epatocarcinoma. 124
-smooth-muscle actin expression in chronic viral hepatitis before and after interferon therapy 123
Gestione delle infezioni da virus epatite B secondo le linee guida nazionali ed internazionali. 123
Relationship between HBcAg in serum and liver and HBV replication in patients with HBsAg-positive chronic liver disease 122
Serum HBV-DNA in anti-HBe positive patients detected by filter and liquid phase hybridization assays 122
How to predictic the outcome of chronic hepatitis B 122
T and K cell function in acute and chronic hepatitis 122
Hepatitis C and cirrhosis 121
[The side effects associated with the interferon-alpha therapy of chronic viral hepatitis] 120
Progression to cirrhosis, hepatocellular carcinoma and liver related mortality in chronic hepatitis B patients in Italy. 120
Clinical and virological profiles in patients with multiple hepatitis virus infections. 119
Antifibrogenic effect of combination interferon plus ribavirin treatment in patients with chronic hepatitis C 119
TLR4 rs4986790 A>G . genetic polymorphisms predict liver fibrosis severity in Caucasian patients with chronic hepatitis B. 119
Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP) 118
Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis 118
Natural history of chronic hepatitis B virus and Hepatitis delta virus infection and disease 118
Cellular immunity to the hepatitis B virion in acute and chronic infection 118
Carriage of the EGF rs4444903 A>G functional polymorphism associates with disease progression in chronic HBV infection. 117
Antibody dependent cellular cytotoxicity (ADCC) in acute hepatitis B and in chronic active hepatitis 116
Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. 116
Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage 116
Virus replication and liver disease in chronic hepatitis B virus infection 115
Heteroimmune and autoimmune reactions to liver cell surface antigens in the pathogenesis of acute and chronic hepatitis 115
Natural history of hepatitis B 115
Influence of GB virus-C/Hepatitis G Virus infection on the long term course of chronic hepatitis B 114
Morbidity and mortality in compensated cirrhosis type C: relationship to interferon alpha therapy 114
Comparison of morbidity and mortality in HBsAg positive cirrhosis with or without hepatitis delta virus superinfection 114
Interlukin-28B polymorphisms, IP-10, viral load and age predict the outcome of therapy in genotype 1 hepatitis C virus under real-life conditions 114
Efficacy of consensus interferon (CIFN) plus ribavirin (RBV) as initial treatment for chronic hepatitis C patients: an italian multicentre study 114
Effectiveness of interferon alfa on the clinical course of caucasian patients with viral compensated cirrhosis 114
Hepatitis C virus genotype and risk of hepatocellular carcinoma in compensated cirrhosis type C 113
Natural history of HBV and HDV infection and liver disease 113
Baseline serum vitamin D levels strongly predict the achievement of sustaiend viral response after antiviral therapy in patients with chronic hepatiits C 113
HLA-DR expression in liver in human HIV infection 112
Changes in serum hepatitis B virus (HBV) DNA positivity in chronic HBV infection: results of a long-term follow-up study of 138 patients 112
The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. 112
Totale 13.797
Salva come PNG Salva come JPEG
Categoria #
all - tutte 117.479
article - articoli 51.051
book - libri 0
conference - conferenze 55.547
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 10.881
Totale 234.958
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.229 0 0 0 0 0 260 16 359 152 11 356 75
2021/20222.414 148 544 11 39 295 76 110 174 172 75 263 507
2022/20234.650 434 301 540 931 438 1.052 34 288 451 22 114 45
2023/20242.363 102 186 166 361 398 301 62 114 4 33 456 180
2024/20256.028 396 508 45 911 387 83 194 264 1.044 403 422 1.371
2025/20268.628 1.307 709 942 2.155 3.383 132 0 0 0 0 0 0
Totale 36.788